Urogen Pharma Profit Margin 2016-2021 | URGN
Current and historical gross margin, operating margin and net profit margin for Urogen Pharma (URGN) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Urogen Pharma net profit margin as of June 30, 2021 is -349.05%.
|Urogen Pharma Annual Profit Margins
|Urogen Pharma Quarterly Profit Margins
||Medical - Biomedical and Genetics
UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel.